Study of Capmatinib Efficacy in Comparison With Docetaxel in Previously Treated Participants With Non-small Cell Lung Cancer Harboring MET Exon 14 Skipping Mutation
NCT04427072 · GeoMETry-III Phase 3Terminated
- Lead sponsor
- Novartis Pharmaceuticals (Industry)
- Enrollment
- 22 (actual)
- Start date
- 25 Sep 2020
- Primary completion
- 15 Feb 2023 (actual)
- Study completion
- 6 Nov 2023
- Last update posted
- 16 May 2025
Design
- Study type
- Interventional
- Primary purpose
- Treatment
- Allocation
- Randomized
- Intervention model
- Crossover
- Masking
- None
- Arms
- 2
Interventions
- Capmatinib Drug
- Docetaxel Drug
Conditions and primary outcome
- Carcinoma, Non-Small-Cell Lung
Primary outcome
Progression-free Survival (PFS) Per Blinded Independent Review Committee (BIRC) Using RECIST v1.1 (From randomization to the date of first documented progression or death from any cause, whichever came first, assessed up to approximately 21 months)
Posted results on ClinicalTrials.gov
Source: ClinicalTrials.gov results for NCT04427072 (opens in a new tab)· Licence: public-domain
First posted · Last update posted · Imported from ClinicalTrials.gov download 2026-10-25
Primary outcomes with a statistical analysis
No primary outcome with a statistical analysis is posted for this study.
Serious adverse events
Time frame: From day of first dose of study medication to last dose of study medication plus 30 days, up to approximately 117 weeks. Deaths were collected in the post-treatment phase from 31 days after last dose of study medication until the end of the study, up to approximately 36 additional weeks. These were not considered AEs.
| Group | Affected | At risk |
|---|---|---|
| Capmatinib (On-treatment) | 3 | 15 |
| Docetaxel (On-treatment) | 2 | 6 |
| Capmatinib Extension Crossover Treatment (On-treatment) | 1 | 5 |
| Capmatinib (Post-treatment Survival Follow-up) | 0 | 0 |
| Docetaxel (Post-treatment Survival Follow-up) | 0 | 0 |
Posted results as ClinicalTrials.gov prints them: primary outcome analyses and serious adverse event totals only. Registry facts, not reviewed by HealthTrade and not investment advice; filing-derived results are listed separately.
Source: ClinicalTrials.gov, U.S. National Library of Medicine. Listing a study does not mean NLM has evaluated it.
Results from company and journal sources
No editor-confirmed results are on record for this study.
Publications
No PubMed citation lists NCT04427072.
CT-VCA trial quality
About CT-VCALoading CT-VCA scores…
Data integrity
Compare what the registry, company releases, FDA documents and publications say about this study.
Drugs on HealthTrade
Source
- NCT04427072 on ClinicalTrials.gov (opens in a new tab) Licence: public-domain. Read
Source: ClinicalTrials.gov, U.S. National Library of Medicine. Listing a study does not mean NLM has evaluated it.
Nothing on this page is medical or investment advice.